Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%

Healthcare

Page 48
  1. Mar 13, 2026 · 20:15 · CHS

    Comprehensive Healthcare Systems Announces Extension of Second Tranche of Private Placement

    Comprehensive Healthcare Systems Announces Extension of Second Tranche of Private Placement

    01
  2. Mar 13, 2026 · 18:43 · NURS

    Hydreight closes acquisition of 800,000 Insu units

    Hydreight closes acquisition of 800,000 Insu units

    02
  3. Mar 13, 2026 · 17:06 · SHRX

    Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering

    Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering

    03
  4. Mar 13, 2026 · 16:15 · NURS

    Hydreight Technologies Closes Strategic Investment in Insu Therapeutics

    Hydreight Technologies Closes Strategic Investment in Insu Therapeutics

    04
  5. Mar 13, 2026 · 10:30 · PRN

    CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

    CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

    05
  6. Mar 13, 2026 · 04:44 · ONCO

    Onco-Innovations closes $1.21M private placement

    Onco-Innovations closes $1.21M private placement

    06
  7. Mar 12, 2026 · 21:03 · EPRX

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

    07
  8. Mar 12, 2026 · 17:30 · RX

    BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026

    BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026

    08
  9. Mar 12, 2026 · 17:00 · ONCO

    Onco-Innovations Announces Closing of Private Placement

    Onco-Innovations Announces Closing of Private Placement

    09
  10. Mar 12, 2026 · 17:00 · CPH

    Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings

    Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings

    10
  11. Mar 12, 2026 · 16:15 · NGEN

    NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

    NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

    11
  12. Mar 12, 2026 · 15:28 · RKV

    Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

    Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

    12
  13. Mar 12, 2026 · 07:00 · DR

    Medical Facilities Corporation Reports Fourth Quarter and FY 2025 Results

    Medical Facilities Corporation Reports Fourth Quarter and FY 2025 Results

    13
  14. Mar 12, 2026 · 06:30 · HLS

    HLS Therapeutics Announces Fiscal 2025 Financial Results

    HLS Therapeutics Announces Fiscal 2025 Financial Results

    14
← Newer Older →